Viridian Therapeutics, Inc./DE balance sheet VRDN

Annual Quarterly

As of Sep 30, 2026, Viridian Therapeutics, Inc./DE had total assets of $1.0 billion and total liabilities of $448.0 million. Total assets were up 78.2% from a year earlier. Stockholders' equity was $580.7 million. It held $955.2 million in cash and investments against $806,000 of total debt, net cash of $954.4 million. The current ratio, current assets divided by current liabilities, was 14.46.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Assets
Cash	173	—	—	—	—	—	—	—
Short-term investments	782 +143.5%	817 +83.1%	586 +12.6%	662 +7.2%	321 -41.9%	446 -3.8%	520 -0.2%	618 +65.0%
Cash and investments	955 +197.3%	817 +83.1%	586 +12.6%	662 +7.2%	321 -41.9%	446 -3.8%	520 -0.2%	618 +65.0%
Receivables	30	—	—	—	—	—	—	—
Inventory	0	—	—	—	—	—	—	—
Total current assets	1,013 +77.1%	1,081 +86.8%	785 +19.4%	894 +21.1%	572 -25.5%	579 -0.5%	657 +4.9%	738 +51.8%
Property and equipment, net	3 +164.2%	3 +153.4%	1 -2.8%	1 -0.6%	1 -12.8%	1 -27.9%	1 -23.9%	1 -26.1%
Total assets	1,029 +78.2%	1,097 +88.4%	789 +19.4%	899 +21.1%	577 -25.2%	582 -0.6%	661 +4.9%	742 +51.4%
Liabilities and equity
Accounts payable	9 -7.6%	9 +1.6%	13 +242.6%	9 +305.2%	10 +58.8%	9 +171.3%	4 +45.2%	2 -4.3%
Total current liabilities	70 +38.2%	64 +21.3%	52 +53.6%	71 +47.7%	51 +22.6%	53 +43.0%	34 +29.1%	48 +79.7%
Total liabilities	448 +504.0%	435 +548.0%	153 +170.8%	177 +150.5%	74 +15.2%	67 +19.2%	57 +18.1%	71 +46.2%
Stockholders' equity	581 +15.5%	662 +28.5%	636 +5.2%	722 +7.5%	503 -28.9%	515 -2.7%	604 +3.8%	672 +51.9%
Debt
Debt due within a year	—	—	—	—	—	8 +184.6%	—	—
Long-term debt	—	—	—	—	21 +1.8%	12 -29.4%	21	21
Lease liabilities	1 -72.1%	1 -68.5%	1 -69.5%	3 +6.9%	3 +4.9%	2 +6.5%	2 +48.6%	3 +38.5%
Total debt	1 -96.6%	1 -96.9%	1 -96.8%	3 -88.3%	24 +2.2%	23 +2.1%	23 +5.2%	23 +4.9%
Net cash	954 +220.8%	816 +92.9%	585 +17.7%	660 +10.9%	297 -43.8%	423 -4.1%	497 -0.5%	595 +68.8%
Ratios
Current ratio	14.46x	16.95x	15.15x	12.65x	11.28x	11.01x	19.49x	15.43x
Debt to equity	0.00x	0.00x	0.00x	0.00x	0.05x	0.04x	0.04x	0.03x
Return on equity	-78.11%	-58.45%	-56.70%	-47.44%	-60.04%	-66.79%	-51.01%	-40.19%
Return on assets	-44.09%	-35.27%	-45.70%	-38.09%	-52.32%	-59.08%	-46.65%	-36.36%
Book value per share	5.12	5.85	6.21	7.09	6.12	6.31	7.41	8.29

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: VRDN (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Waltham, MA
SEC filer status: Large accelerated filer
SEC CIK: 1590750
Former names: MIRAGEN THERAPEUTICS, INC. (until Jan 15, 2021); SIGNAL GENETICS, INC. (until Feb 10, 2017); SIGNAL GENETICS LLC (until Jul 9, 2014)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.